Investigational New Drugs

Anti-tumoral effect of arsenic compound, sodium metaarsenite (KML001), in non-Hodgkin’s lymphoma: an in vitro and in vivo study

Jin Sun Yoon, Deok Won Hwang, Eun Shil Kim, Jung Soon Kim, Sujong Kim, Hwa Jin Chung, Sang Kook Lee, Jun Ho Yi, Jieun Uhm, Young Woong Won, Byeong Bae Park, Jung Hye Choi, Young Yiul Lee

7-formyl-10-methylisoellipticine, a novel ellipticine derivative, induces mitochondrial reactive oxygen species (ROS) and shows anti-leukaemic activity in mice

Eileen G. Russell, Jianfeng Guo, Elaine C. O’Sullivan, Caitriona M. O’Driscoll, Florence O. McCarthy, Thomas G. Cotter

Coibamide A, a natural lariat depsipeptide, inhibits VEGFA/VEGFR2 expression and suppresses tumor growth in glioblastoma xenografts

Jeffrey D. Serrill, Xuemei Wan, Andrew M. Hau, Hyo Sang Jang, Daniel J. Coleman, Arup K. Indra, Adam W. G. Alani, Kerry L. McPhail, Jane E. Ishmael

Determination of unbound fraction of pazopanib in vitro and in cancer patients reveals albumin as the main binding site

Diane-Charlotte Imbs, Marie-Noelle Paludetto, Sylvie Négrier, Helen Powell, Thierry Lafont, Melanie White-Koning, Etienne Chatelut, Fabienne Thomas

LY2603618, a selective CHK1 inhibitor, enhances the anti-tumor effect of gemcitabine in xenograft tumor models

Darlene Barnard, H. Bruce Diaz, Teresa Burke, Gregory Donoho, Richard Beckmann, Bonita Jones, David Barda, Constance King, Mark Marshall

Plasma and cerebrospinal fluid pharmacokinetics of vincristine and vincristine sulfate liposomes injection (VSLI, marqibo®) after intravenous administration in Non-human primates

Nirali N. Shah, Diane E. Cole, Cynthia M. Lester-McCully, Alan S. Wayne, Katherine E. Warren, Brigitte C. Widemann

Phase I trial of volasertib, a Polo-like kinase inhibitor, in Japanese patients with advanced solid tumors

Hiroshi Nokihara, Yasuhide Yamada, Yutaka Fujiwara, Noboru Yamamoto, Hiroshi Wakui, Shinji Nakamichi, Satoru Kitazono, Kohei Inoue, Akiko Harada, Tillmann Taube, Yoshito Takeuchi, Tomohide Tamura

Phase I, dose-escalating study of elisidepsin (Irvalec®), a plasma membrane-disrupting marine antitumor agent, in combination with erlotinib in patients with advanced malignant solid tumors

Sanjay Goel, Santiago Viteri, Teresa Morán, Cinthya Coronado, Jorge Luis Iglesias Dios, Bernardo Miguel-Lillo, Eva M. Fernández-García, Rafael Rosell

A phase I study of MK-5108, an oral aurora a kinase inhibitor, administered both as monotherapy and in combination with docetaxel, in patients with advanced or refractory solid tumors

Manik Amin, Susan E. Minton, Patricia M. LoRusso, Smitha S. Krishnamurthi, Cheryl A. Pickett, Jared Lunceford, Darcy Hille, David Mauro, Mark N. Stein, Andrea Wang-Gillam, Lauren Trull, A. Craig Lockhart

Phase I trial of FOLFIRI in combination with sorafenib and bevacizumab in patients with advanced gastrointestinal malignancies

Joleen M. Hubbard, George Kim, Mitesh J. Borad, Elizabeth Johnson, Rui Qin, Janet Lensing, Suneetha Puttabasavaiah, John Wright, Charles Erlichman, Axel Grothey

A phase I trial of ANG1/2-Tie2 inhibitor trebaninib (AMG386) and temsirolimus in advanced solid tumors (PJC008/NCI♯9041)

Joanne W. Chiu, Sebastien J. Hotte, Christian K. Kollmannsberger, Daniel J. Renouf, David W. Cescon, David Hedley, Sue Chow, Jeffrey Moscow, Zhuo Chen, Meghan Perry, Ivan Diaz-Padilla, David Tan, Hal Hirte, Elaine McWhirter, Helen Chen, Lillian L. Siu, Philippe L. Bedard

A phase II trial of ganetespib, a heat shock protein 90 Hsp90) inhibitor, in patients with docetaxel-pretreated metastatic castrate-resistant prostate cancer (CRPC)-a prostate cancer clinical trials consortium (PCCTC) study

Manish K. Thakur, Lance K. Heilbrun, Shijie Sheng, Mark Stein, Glenn Liu, Emmanuel S. Antonarakis, Ulka Vaishampayan, Sijana H. Dzinic, Xiaohua Li, Stacy Freeman, Daryn Smith, Elisabeth I. Heath

Trastuzumab and bevacizumab combined with docetaxel, oxaliplatin and capecitabine as first-line treatment of advanced HER2-positive gastric cancer: a multicenter phase II study

Didier Meulendijks, Laurens V. Beerepoot, Henk Boot, Jan Willem B. de Groot, Maartje Los, James E. Boers, Steven A. L. W. Vanhoutvin, Marco B. Polee, Aart Beeker, Johanna E. A. Portielje, Robert S. de Jong, Swan H. Goey, Maria Kuiper, Karolina Sikorska, Jos H. Beijnen, Margot E. Tesselaar, Jan H. M. Schellens, Annemieke Cats

Effect of CH-35, a novel anti-tumor colchicine analogue, on breast cancer cells overexpressing the βIII isotype of tubulin

Lee-Chuan C. Yeh, Asok Banerjee, Veena Prasad, Jack A. Tuszynski, Alexander L. Weis, Tamas Bakos, I-Tien Yeh, Richard F. Ludueña, John C. Lee

Acknowledgement of Reviewers 2015